Bicara Therapeutics (NASDAQ:BCAX) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline its ...

Krystal Biotech is upgraded to Strong Buy as Vyjuvek sales surge and catalysts build. Click here to know more.

Data shows iberdomide combination therapy delivers progression free survival and safety in relapsed and refractory multiple ...

Advancing robust clinical pipeline of novel therapeutics for muscular dystrophies and serious cardiac conditions - - Presenting at the 44th Annual J.P. Morgan Healthcare ...

Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials - This next-generation anthracycline demonstrates safety and promising early activity in treating multiple ...

Researchers are uncovering how disrupted glutamatergic synapses drive diverse forms of intellectual disability, revealing new ...

A massive NASCAR Rule Book update was posted on Friday and removes every instance of ‘the playoffs’ and ‘playoff points’ to ...

With Moleculin’s WP1066 oral formulation, an externally funded Phase 2 trial in combination with radiation treating GBM, a form of brain cancer, is recruiting and treating subjects at Northwestern ...

N2OFF’s wholly-owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for ...

Prefoldin 5 stabilises neuronal microtubules and suppresses Tau-mediated neurotoxicity, offering a potential therapeutic target for tauopathies.

Sensorineural hearing loss (SNHL) is a highly prevalent sensory disorder globally, affecting over 1.5 billion people, with a ...

Objective: To compare and analyze the differences in vaginal microecological characteristics between populations with ...